Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Specialty Market Focus Provides Refuge In “Unstable Environment”

Executive Summary

Roche's return to prominence in the primary care market will wait until at least 2006, the company indicated during a July 24 analyst meeting in Zurich
Advertisement

Related Content

Roche Vision Of Rx Future Includes IT And China, But Not Large Sales Force
Roche Vision Of Rx Future Includes IT And China, But Not Large Sales Force
Xenical OTC Switch Plans Underway; GSK Pays $100 Mil. For Rights
The 10% Solution: Roche Cuts U.S. Sales Force, Schering Reduces Payroll
Reimportation In North America Is Inevitable, Roche Suggests; EU Is Model
Roche View On Biogenerics: “They Will Come,” But Process Won’t Be Simple
Roche/GSK Boniva Launch Will Await Less Frequent Dose Approval
Roche/GSK Boniva Launch Will Await Less Frequent Dose Approval
Roche Tries Genentech Formula In Japan: Chugai Deal Follows 1990 Model
Roche Pares Back To Specialty Care: U.S. Sales Force Will Be Cut By 24%
Advertisement
UsernamePublicRestriction

Register

PS042213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel